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Abstract
Background—While the emergence of chronic and mucoid Pseudomonas aeruginosa (Pa) 
infection are both associated with poorer outcomes among CF patients, their relationship is poorly 
understood. We examined the longitudinal relationship of incident, chronic and mucoid Pa in a 
contemporary, young CF cohort in the current era of Pa eradication therapy.
Methods—This retrospective cohort was comprised of patients in the U.S. CF Foundation Patient 
Registry born 2006–2015, diagnosed before age 2, and with at least 3 respiratory cultures 
annually. Incidence and age-specific prevalence of Pa infection stages (initial and chronic [≥ 3 Pa+ 
cultures in prior year]) and of mucoid Pa were summarized. Transition times and the interaction 
between Pa stage and acquisition of mucoid Pa were examined via Cox models.
Results—Among the 5,592 CF patients in the cohort followed to a mean age of 5.5 years, 64% 
(n=3,580) acquired Pa. Of those, 13% (n=455) developed chronic Pa and 17% (n=594) cultured 
mucoid Pa. Among those with mucoid Pa, 36% (211/594) had it on their first recorded Pa+ 
culture, while mucoid Pa emerged at or after entering the chronic stage in 12% (73/594). Mucoidy 
was associated with significantly increased risk of transition to chronic Pa infection (HR=2.59, 
95% CI 2.11, 3.19).
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Conclusions—Two-thirds of early-diagnosed young children with CF acquired Pa during a 
median 5.6 years of follow up, among whom 13% developed chronic Pa and 17% acquired mucoid 
Pa. Contrary to our hypothesis, 87% of young children who developed mucoid Pa did so before 
becoming chronically infected.
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INTRODUCTION
While survival continues to improve in cystic fibrosis (CF), the major cause of morbidity 
and mortality remains progressive lung disease due to chronic endobronchial bacterial 
infection, inflammation and structural airway damage. Pseudomonas aeruginosa (Pa) is the 
sentinel respiratory pathogen in CF; by adulthood 70% of CF patients are infected (1), and 
Pa infection has been linked to poorer outcomes and greater mortality (2, 3). The 
progression of Pa infection is frequently characterized in stages: initial to intermittent to 
chronic (4). While initial Pa infection has no clear effect on clinical outcomes (5), chronic 
infection has been associated with lower lung function, greater structural damage on chest 
imaging and poorer nutritional status (6–8). Pa infection in the CF lung can also be 
characterized by phenotypic changes, the best-known being mucoidy. Like chronic infection, 
mucoidy has clearly been associated with worse clinical outcomes (9–11). While the 
accepted belief is that chronic Pa infection precedes mucoid infection (12, 13), in fact, the 
longitudinal relationship between the emergence of chronic Pa infection and of mucoidy has 
only been minimally evaluated (14), and recent studies suggest that this paradigm might be 
overly simplistic (15–17).
Among infants born between 1985 and 1994 enrolled in the Wisconsin Neonatal Screening 
Project, more than 80% had acquired Pa by age 4 (10). Since that study (and in part based on 
its findings), aggressive antibiotic treatment of initial Pa infection to delay or prevent 
chronic / mucoid infection has become standard of care in the U.S. (18–21). Recent U.S. 
nationwide data show reduced age-specific prevalence and incidence of Pa over the past 
decade compared to the decade prior (1), but trends in the prevalence of chronic Pa and 
mucoid Pa were not evaluated.
We utilized the CF Foundation Patient Registry (CFFPR) to describe stages of Pa infection 
and mucoid Pa in a young CF cohort in the current era of Pa eradication therapy. The 
objectives of this analysis were to (1) characterize the emergence and age-specific 
prevalence of Pa, chronic Pa and mucoid Pa in young CF patients and (2) examine the 
relationship between stages of Pa infection and mucoidy. We hypothesized that emergence 
of mucoid Pa would occur predominantly following the development of chronic infection 
among young people with CF.
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METHODS
Study Design and Population
The CFFPR is a comprehensive repository of clinical and epidemiological data collected 
from CF patients across the United States since 1966 (22, 23). In 2003, data began to be 
collected at each clinic encounter (typically quarterly) rather than annually, and in 2006 
information on chronic inhaled antibiotic use was added to the CFFPR (22). We therefore 
performed a retrospective, longitudinal cohort study using CFFPR data from 2006 to 2015. 
Because we aimed to characterize the transition from incident to chronic and mucoid Pa, we 
enrolled patients born on or after January 1, 2006 who were diagnosed and had first 
encounter data recorded in the CFFPR by age two. Because detection of Pa, mucoid Pa, and 
the definition of chronic Pa are all highly dependent on respiratory culture frequency, the 
cohort was further restricted to those with at least three quarters (3-month intervals) with 
respiratory cultures recorded per year for a minimum of two years, or if born in 2015, at 
least three quarters with cultures recorded that year (i.e., those who were generally following 
U.S. CF Foundation Care Guidelines calling for quarterly cultures (21).)
Data and variables
Respiratory culture data were evaluated by age quarter intervals (i.e., four quarters per each 
year of age). The presence of at least one Pa+ culture in a given age quarter defined that age 
quarter as positive for Pa. For each patient the age quarter of initial Pa was defined as the 
quarter of first lifetime isolation of Pa (i.e. incident Pa). Because left censoring can impact 
Pa incidence estimates, a sensitivity cohort was also analyzed excluding patients if their first 
recorded culture was positive for Pa. The age of first chronic infection was defined as the 
first age quarter in which at least three age quarters in the preceding year were Pa+ (e.g. 3/3, 
3/4, or 4/4 cultures positive for Pa in the preceding year). Following first chronic infection, 
the subsequent year was assessed to determine reversion to Pa free (defined as zero Pa+ 
cultures in the year, with cultures recorded in at least one age quarter). The age quarter of 
first mucoid Pa recorded in the CFFPR was also calculated for each patient. The CFFPR 
does not record acute courses of inhaled or oral antibiotics, but recorded use of chronic 
inhaled antibiotics (tobramycin, aztreonam, or other) during the year a person became 
chronically infected with Pa was summarized. Demographic and diagnostic information 
included sex, race, ethnicity, diagnosis method and age, F508del mutation status and CF 
transmembrane conductance regulator (CFTR) functional class (24, 25).
Statistical Methods
Age-specific prevalence of Pa was calculated in each age category. Kaplan-Meier curves 
were generated age of initial, first mucoid, and first chronic Pa, and for transition times from 
initial to chronic and mucoid Pa infection, and Cox proportional hazards (PH) models were 
fit. All p-values are two-sided. See online Supplemental Material for details, sensitivity 
analyses and Kaplan-Meier curves comparing time to Pa acquisition by CFTR mutation 
functional class.
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RESULTS
Demographics and Pa Prevalence & Incidence
Of the 7070 CF patients in the CFFPR born between 2006 and 2015, 5592 met inclusion 
criteria (Table 1). Sixty six percent were diagnosed through prenatal or newborn screening. 
Mean age at diagnosis was 1 month and mean age of first recorded respiratory culture in the 
CFFPR was 0.29 years (SD=0.22). Average follow-up time (from birth until last recorded 
culture) was 5.5 years (SD =2.5, median 5.6, range = 0.6, 9.9 years); 43% of the cohort had 
follow-up to at least 6 years of age and 19% were observed past age 8.
Over all the possible person-age quarters in the cohort, respiratory cultures were recorded in 
82%. Cultures were predominantly from oropharyngeal swabs (84%), with sputum and 
bronchoalveolar lavage samples less common, 13% and 2% respectively. The prevalence of 
non-mucoid Pa by age was relatively constant across each age interval (0–9 years), ranging 
from 15 to 26% (Figure 1a), with slight decreases after 2 years of age. The prevalence of 
mucoid Pa, however, rose steadily with age, from 1% in the first year to approximately 8% 
at age 9 (Figure 2a). Similarly, the prevalence of chronic Pa rose steadily from <1% in the 
first year to 6.7% by age 9 (Figure 1b).
More than half of all patients (3580/5592=64%) became Pa positive during the observation 
period. Kaplan-Meier curves for time to initial Pa, first mucoid and first chronic Pa as well 
as transition times are shown in Figures 2a–e. The median age at initial Pa for all 5,592 
patients was 2.6 years (95% CI =(2.4, 2.9), Figure 2a). Approximately one in ten patients 
developed mucoid Pa (594/5,592=10.6%), or 16.6% of the 3,580 Pa+ patients. Notably, 
35.5% (211/594) of those with mucoid Pa acquired it at the time of first Pa positive culture. 
Among all patients, 8.1% (455/5,592) developed chronic Pa, or 12.7% of the Pa+ patients. In 
a sensitivity analysis excluding the 472 participants whose first recorded respiratory culture 
was Pa+, results were essentially unchanged (Supplemental Table 1). Among those meeting 
the definition for chronic Pa, 83% (n=376) reported inhaled antibiotic use in the concurrent 
year, with the vast majority being inhaled tobramycin (94.7% [356/376]); 17.3% (65/376) 
reported inhaled aztreonam and 2% other inhaled antibiotic use. In the year after meeting the 
chronic definition, 27% (124/455) reverted to Pa free.
Table 1 compares the characteristics of patients who remained Pa free versus those who 
acquired Pa (N=2,012 vs. 3,580), mucoid Pa (N=594) and chronic Pa (N=455). Compared to 
patients who remained Pa free, patients who acquired Pa were more likely to have two 
functional classes I to III CFTR mutations (76% vs. 64%), less likely to be diagnosed by 
newborn screening (58% vs. 67%), were followed for a longer duration (mean 6.0 vs. 4.6 
years) and had more quarters with cultures recorded. Similarly, compared to patients who 
remained Pa free, those who developed mucoid Pa or chronic infection were more likely to 
be followed for a longer duration (mean=6.9–7.0 years) and were more likely to have two 
severe CFTR mutations (79–81%).
Temporal Relationships between Chronic and Mucoid Pa
Table 2 summarizes the multiple transition patterns observed between initial, chronic and 
mucoid Pa infection in our cohort. Given the young age of our cohort and relatively short 
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observation period, most patients who acquired Pa did not go on to develop chronic or 
mucoid Pa (column 1). Among those who did progress, progression to mucoid Pa only was 
the most common pattern (N=371; 10% of Pa+ patients), occurring more often than 
transition to chronic Pa only (N = 232, 6%). We hypothesized that young patients with CF 
would culture mucoid Pa after becoming chronically infected; however, only 10% of those 
who developed mucoid Pa did so after reaching the chronic Pa stage and another 2% had 
mucoid co-occur with chronic Pa infection (Table 2, last column). First mucoid Pa actually 
preceded chronic Pa infection in 87% of those with mucoid Pa (62% developed mucoid Pa 
only, while 25% developed mucoid Pa and then chronic Pa).
The risks of progressing to chronic Pa and mucoid Pa were inter-related (Supplemental 
Table 2). Entering the chronic Pa stage did not significantly increase the risk of developing 
mucoid Pa (hazard ratio (HR) = 0.99, 95% CI= 0.76, 1.28). However, acquiring mucoid Pa 
increased the risk of developing chronic Pa (HR=2.59; 95% CI=2.11, 3.19, p<0.001), 
adjusted CFTR mutation functional class, race, sex, diagnosis type, and number of 
respiratory cultures. In addition, high risk CFTR functional class (2 mutations in class I to 
III) was associated with earlier acquisition of initial Pa, chronic Pa, mucoid Pa and transition 
times from initial to both chronic and mucoid Pa compared to residual function (at least 1 
class IV or V mutation) (Supplemental Figure 1a–e).
DISCUSSION
In this analysis, we characterized the emergence of chronic Pa and mucoid Pa as two, often 
independent, stages of Pa infection clearly associated with poorer outcomes. We focused on 
young patients, to capture the progression from initial to chronic and mucoid Pa, and 
because the outcomes of chronic or mucoid Pa might be easier to alter with aggressive 
treatment in young children than in older patients with more established Pa infection.
In our large, contemporary U.S. cohort of children diagnosed with CF before age 2 and 
followed for a median of 6 years, nearly two-thirds acquired Pa. In contrast to studies 
conducted prior to widespread use of Pa eradication regimens (10), age-specific prevalence 
of non-mucoid Pa from birth to age 9 ranged from 26 to 15%. Progression to chronic Pa and 
mucoid Pa occurred in a substantial minority of those who acquired Pa (13% and 17%, 
respectively). In addition, the prevalence of both chronic and mucoid Pa rose with age, 
increasing from <1% in the first year of life to 7% at age 9 for chronic Pa and 8% for 
mucoid Pa.
Prior publications evaluating the emergence or prevalence of chronic Pa in CF have 
primarily focused on older patients (4, 6, 7, 26). More recently, in the EPIC trial of 
standardized Pa eradication regimens for newly acquired Pa (mean age 7.6 years) (27), 
chronic Pa developed in 23% of those who achieved sustained eradication in the original 
trial and 56% of those who did not (median follow up of 5 years) (16). The proportions 
acquiring mucoid Pa were 17% and 33%, respectively. The lower prevalence of chronic and 
mucoid Pa in our study was likely explained by the younger age and shorter follow up of our 
cohort.
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Mucoidy is a well-characterized adaptation of Pa to the CF airway, due to excessive 
production of extracellular polysaccharide alginate. The emergence of mucoid Pa has been 
clearly implicated in poorer clinical outcomes in CF patients (9–11). A widely held 
paradigm is that initial Pa progresses first to chronic and then to mucoid Pa (12, 13). 
However, our results and those of others (14, 15, 28) suggest that this paradigm may be 
overly simplistic. In the Australasian CF Bronchoalveolar Lavage (ACFBAL) randomized 
controlled trial of BAL-directed therapy in infants with CF, 7% of lower airway isolates 
were mucoid even though none of the children met the definition of chronic Pa infection 
(15). Similarly, in the Australian AREST CF study involving annual BAL in CF patients <6 
years of age, 18% of initial lower airway Pa was mucoid (28). A recent evaluation of 
phenotypes of upper airway Pa isolates from children enrolled in the EPIC Observational 
Study identified mucoidy in 8% of cultures of newly detected Pa and found a significant 
relationship between mucoidy and risk of subsequent pulmonary exacerbation requiring IV 
antibiotics that was consistent across infection stage (14). Finally, a study of the phenotypic 
characteristics of incident Pa isolates in children with CF in Toronto showed mucoidy to be 
significantly associated with failure of Pa eradication regimens, occurring in 71% of those 
who failed to eradicate vs. 31% who achieved eradication (17).
In our cohort, we specifically examined the temporal relationships of initial, mucoid and 
chronic Pa and found multiple patterns of transition. Contrary to our hypothesis, among 
those developing mucoid Pa, it preceded chronic Pa in 87%; indeed, 36% had mucoid Pa at 
the time of first lifetime Pa (despite limiting our cohort to those with a respiratory culture 
recorded prior to age two), even when those whose first recorded culture was Pa+ were 
excluded. Taken together, these studies clearly demonstrate that mucoidy can occur early in 
Pa infection and can adversely affect clinical outcomes, suggesting it could be an important 
indicator of disease progression risk even in young patients without chronic infection, and 
may increase the risk of chronic infection because of its difficulty to treat.
In the most extensive prior longitudinal evaluation of mucoidy in CF, 56 children in the 
Wisconsin Neonatal Screening Trial born between 1985 and 1994 (prior to routine Pa 
eradication regimens) were followed to age 16 (10). Non-mucoid and mucoid Pa were 
acquired at median ages of 1.0 and 13.0 years, respectively. The median transition time from 
non-mucoid to mucoid Pa was 10.9 years, and appeared to be extended by anti-Pa 
antibiotics. Transition to mucoid Pa correlated with deterioration in cough scores, chest 
radiograph scores and pulmonary function; in contrast, there was no correlation of 
acquisition of non-mucoid Pa with clinical deterioration. In our contemporary cohort, the 
median age at initial Pa was 1.4 years among those who acquired Pa and 2.6 years overall, 
similar to the Wisconsin cohort. While the age-specific prevalence of Pa rose dramatically 
from 30% at age <1 to >90% at age 7 in the Wisconsin cohort, it was stable at 17 to 26% for 
each year of age in our cohort, perhaps reflecting the efficacy of Pa eradication therapies, 
infection control and other improvements in CF care over the past 20 years. In Wisconsin, 
non-mucoid Pa preceded mucoid Pa in all participants. The large size of our contemporary 
cohort, the variable specimen types cultured for Pa (predominantly oropharyngeal swabs), 
and the variability between sites in interpreting and recording mucoidy might partially 
explain why we observed some cases of mucoid Pa acquisition at the time of initial Pa. 
While the prevalence of mucoid Pa reached 20% at age 8 and nearly 40% at age 10 in the 
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Wisconsin cohort, in our cohort the age-specific prevalence of mucoid Pa was no higher than 
8% up to age 10 years. This difference in prevalence might imply that the transition time to 
mucoid Pa is longer now than it was 20 years ago, however, we did not have enough follow-
up to determine overall median time to mucoidy, as only 8% of the cohort acquired mucoid 
Pa.
Not surprisingly, in Cox proportional hazards models, we found mucoidy to be a strong 
predictor of time to chronic Pa infection, though chronic Pa was not a predictor of mucoid 
Pa, perhaps because it was so much more common to develop mucoid Pa prior to chronic Pa. 
We also found high risk CFTR functional class (both mutations in class 1 to 3) to be a 
predictor of earlier acquisition of initial Pa, chronic Pa and mucoid Pa as well as shorter 
transition times from initial to both chronic and mucoid Pa. These results are concordant 
with our previous finding that high risk CFTR functional class was a risk factor for initial Pa 
acquisition in the EPIC Observational Study cohort (29), as well as the finding by Levy, et al 
that the number of F508 del alleles is a risk factor for mucoid Pa acquisition (30).
Strengths of our analysis include the large, nationally representative cohort and longitudinal 
observations. In addition, because cohort participants were born after 2003, the majority 
were diagnosed by newborn screening (widely adopted in U.S. states between 2003 and 
2010), allowing a more complete picture of Pa patterns from very early in life than in prior 
studies.
Our study also has important limitations. First, almost all respiratory cultures (84%) were 
from the upper airway (oropharyngeal) in this largely non-sputum producing cohort, since 
routine bronchoalveolar lavage is not standard of care at U.S. CF centers. Oropharyngeal 
cultures are well known to have relatively good specificity and negative predictive value but 
poor sensitivity and positive predictive value for the presence of Pa in the lower respiratory 
tract (31). Furthermore, oropharyngeal cultures do not reliably predict lower airway 
genotypes (15). Therefore, our results may not be generalizable to lower airway Pa and may 
overestimate Pa prevalence. Secondly, the CFFPR does not capture data on Pa eradication 
treatment, so that we were unable to evaluate whether there was an association between 
antibiotic treatment of newly acquired Pa and risk of chronic or mucoid Pa in our cohort. 
This question has been previously addressed in the long term follow-up study of the EPIC 
Clinical Trial of Pa eradication regimens, in which children who achieved sustained 
eradication of Pa had significantly reduced risks of developing chronic Pa or mucoidy(16). 
Though we do not have individual-level data on Pa eradication regimens, we do have site-
level results of annual surveys of the 59 U.S. CF centers participating in the EPIC 
Observational Study during the same era. In 2008, 79% of sites responded that they 
“always” prescribed anti-pseudomonal antibiotics for newly isolated Pa and an additional 
15% stated that they “often” prescribed these antibiotics. Eradication antibiotics (not 
mutually exclusive) most commonly listed were inhaled tobramycin (98%) and oral 
ciprofloxacin (90%) (M. Rosenfeld, personal communication). Thus, Pa eradication 
regimens were in widespread use during the period of our study.
Another limitation is that our follow up period was relatively short (less than 6 years on 
average). We were therefore unable to determine the median time from incident to mucoid or 
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chronic Pa, and had too little follow up after mucoid or chronic Pa to meaningfully evaluate 
clinical outcomes associated with chronic or mucoid Pa. Follow-up time and culture 
frequency also varied between individuals, potentially introducing length and sampling 
biases, respectively: those with longer observation or more frequent sampling are at higher 
risk of detection of Pa. Mucoidy was evaluated by each site’s clinical microbiology lab, 
potentially introducing misclassification and may have been the reason we observed lower 
mucoidy prevalence than other reports. Our observation that mucoidy in some instances 
preceded chronic infection was in part due to our definition of chronic Pa infection, which 
was achieved at the end of a year in which ≥3 quarters of cultures were Pa+. Among the 150 
cases in which mucoidy preceded the chronic stage, the mean (SD) time from mucoid to 
chronic Pa was 1.7 (1.8) years with a median of 0.75 years (range 0.25, 7.5 years), 
suggesting that in most of those cases, mucoidy appeared at the beginning of the year in 
which chronic infection developed. Finally, defining chronic Pa in our cohort is imperfect 
because of differential follow-up, relatively low culture frequency, and culture type 
(primarily oropharyngeal). We showed that 27% of those who met the definition of chronic 
Pa became Pa free in the following year, suggesting that our definition of chronic Pa is 
somewhat liberal.
In conclusion, in this contemporary large national cohort of young children with CF, we 
found the initial acquisition of Pa was common and occurred at an age very similar to that 
observed prior to the widespread use of Pa eradication regimens, likely reflecting the fact 
that Pa is initially acquired from the environment. Though our patients were young and the 
follow up period relatively brief, we nonetheless observed emergence of chronic Pa in 8% 
and mucoid Pa in 11%. More sensitive Pa detection techniques, better infection control and 
improved Pa eradication regimens could potentially decrease rates of early chronic and 
mucoid Pa and thus improve outcomes in children with CF.
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Figure 1. a–b. Pa prevalence by age
Panel a) overall Pa prevalence (entire bar) and mucoid Pa prevalence (hashed bar), and panel 
b) chronic Pa prevalence. Denominator of number at risk along the bottom
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Figure 2. a–e. Kaplan-Meier curves for acquisition of Pa
a) Age of initial Pa b) age of initial mucoid Pa, c) age of initial chronic Pa, d) transition time 
from initial non-mucoid to mucoid Pa, and e) transition time from initial to chronic Pa.
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Table 2
Transition pattern from initial Pa to chronic Pa and mucoid Pa among: those with any Pa (N=3,580); those 
with any Chronic Pa (N=455); and those with any Mucoid Pa (N=594)
Ever Pa
Positive
Ever
Chronic
Pa
Ever
Mucoid Pa
(N=3,580) (N=455) (N=594)
Initial Pa Only 2754 (77%) – –
Initial Pa → Chronic Only 232 (6%) 232 (51%) –
Initial Pa → Mucoid Only 371 (10%) – 371 (62%)
Initial Pa → Mucoid & Chronic co-occur 11 (<1%) 11 (2%) 11 (2%)
Initial Pa → Chronic → Mucoid 62 (2%) 62 (14%) 62 (10%)
Initial Pa → Mucoid → Chronic 150 (4%) 150 (33%) 150 (25%)
Note: transitions indicate first occurrence of chronic or mucoid Pa
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